. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Kidney Int. 2015 Feb 4;87(6):1250–1257. doi: 10.1038/ki.2014.383

Table 6.

Reasons for Drug Discontinuation by Treatment Assignment

		CKD			No CKD
		Placebo	Niacin	P-value	Placebo	Niacin	P-value
	N	251	254		1444	1464
Discontinued study drug	N (%)	57 (22.7%)	83 (32.7%)	0.012	284 (19.7%)	353 (24.2%)	0.004
Primary reason for drug discontinuation	Flushing, itching	8 (14.0%)	25 (30.1%)		35 (12.3%)	79 (22.4%)
	Liver function test abnormality	0 (0.0%)	1 (1.2%)		5 (1.8%)	4 (1.1%)
	Patient request	22 (36.8%)	24 (28.9%)		115 (40.5%)	102 (29.0%)
	Non-study physician request	8 (14.0%)	9 (10.8%)		27 (9.5%)	40 (11.3%)
	Other clinical reason to discontinue	16 (28.1%)	13 (15.7%)		79 (27.8%)	83 (23.5%)
	Increased glucose	2 (3.5%)	5 (6.0%)		12 (4.2%)	24 (6.8%)
	Gastrointestinal symptoms	1 (1.8%)	5 (6.0%)		11 (3.9%)	21 (5.9%)